EGFR and neoplasm: Studies have shown that patients with high nuclear EGFR levels have poor clinical outcomes in breast cancer [60], which implies that nuclear EGFR may benefit tumours by helping to evade cell surface EGFR-targeted small molecule inhibitors and therapeutic antibodies.